TY - JOUR
T1 - Enkephalinase-inhibitors modulate immune responses
AU - Janković, Branislav D.
AU - Veljić, Jelena
AU - Pesic, Gordana
AU - Marić, Dragan
N1 - Funding Information:
Correspondence to: Branislav D. Jankovik, Immunology Research Center, Vojvode Stepe 458. I1221 Belgrade, Y ugoslavja. This work was supported by the Republic of Serbia Research Fund, Belgrade.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1991
Y1 - 1991
N2 - Exogenous opioid peptides, and enkephalins in particular, modulate a variety of immune performances in vivo and in vitro. In this study, the immunomodulatory role of endogenous opioids was investigated by means of central and peripheral administration of four peptidase inhibitors in the rat. Animals sensitized with sheep red blood cells (SRBC) were daily treated intraperitoneally (i.p.) with 0.2mg/kg or 1 mg/kg of each inhibitor, or intracerebroventricularly (i.c.v.) with 0.02mg/kg and 0.2 mg/kg of bestatin, des-tyrosine-methionine-enkephalin. (Des-Tyr)Met-Enk; and actinion and 0.005 and 0.5mg/kg of N-Carboxymethyl-pheniallanine-leucine, (N-C)Phe-Leu. Controls were injected i.p. and i.c.v. with saline. The results revealed that in animals treated i.p. with 0.2 mg/kg of bestatin and (N-C)Phe-Leu potentiated the plaque-forming cell (PFC) response and hemagglutinin production. In contrast, these immune responses were suppressed by 1 mg/kg. On the other hand, i.p. doses of 0.2 and 1 mg/kg of actinonin and (Des-Tyr)Met-Enk potentiated humoral immune responses. When given i.c.v., all of the inhibitors used exerted clear dose-dependent immunomodulatory effects, i.e. increase in the PFC response and hemagglutinin production when given at lower doses (0.005-0.02 mg/kg), and decrease when injected with higher doses (0.2-0.5 mg/kg). These effects of enkephalin-related peptidase inhibitors, applied i.p. and i.c.v., suggest the involvement of endogenous enkephalins in immune mechanisms.
AB - Exogenous opioid peptides, and enkephalins in particular, modulate a variety of immune performances in vivo and in vitro. In this study, the immunomodulatory role of endogenous opioids was investigated by means of central and peripheral administration of four peptidase inhibitors in the rat. Animals sensitized with sheep red blood cells (SRBC) were daily treated intraperitoneally (i.p.) with 0.2mg/kg or 1 mg/kg of each inhibitor, or intracerebroventricularly (i.c.v.) with 0.02mg/kg and 0.2 mg/kg of bestatin, des-tyrosine-methionine-enkephalin. (Des-Tyr)Met-Enk; and actinion and 0.005 and 0.5mg/kg of N-Carboxymethyl-pheniallanine-leucine, (N-C)Phe-Leu. Controls were injected i.p. and i.c.v. with saline. The results revealed that in animals treated i.p. with 0.2 mg/kg of bestatin and (N-C)Phe-Leu potentiated the plaque-forming cell (PFC) response and hemagglutinin production. In contrast, these immune responses were suppressed by 1 mg/kg. On the other hand, i.p. doses of 0.2 and 1 mg/kg of actinonin and (Des-Tyr)Met-Enk potentiated humoral immune responses. When given i.c.v., all of the inhibitors used exerted clear dose-dependent immunomodulatory effects, i.e. increase in the PFC response and hemagglutinin production when given at lower doses (0.005-0.02 mg/kg), and decrease when injected with higher doses (0.2-0.5 mg/kg). These effects of enkephalin-related peptidase inhibitors, applied i.p. and i.c.v., suggest the involvement of endogenous enkephalins in immune mechanisms.
KW - Antibody
KW - Enkephalinase
KW - Enkephalins
KW - Immunity
KW - Methionine-enkephalin
KW - Peptidase
UR - http://www.scopus.com/inward/record.url?scp=0026185120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026185120&partnerID=8YFLogxK
U2 - 10.3109/00207459108985448
DO - 10.3109/00207459108985448
M3 - Article
C2 - 1774139
AN - SCOPUS:0026185120
SN - 0020-7454
VL - 59
SP - 45
EP - 51
JO - International Journal of Neuroscience
JF - International Journal of Neuroscience
IS - 1-3
ER -